• Kyodo News


Astellas Pharma Inc. and a U.S. pharmaceutical firm said Wednesday they have agreed to develop and commercialize worldwide a drug to treat prostate cancer.

The Japanese drugmaker and Medivation Inc. will work on a “comprehensive development program,” including further studies to develop the U.S. firm’s investigational drug MDV3100 for various stages of prostate cancer, they said.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.